---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-10-25T06:20:33.230313'
end_time: '2026-10-25T06:36:20.921054'
duration_seconds: 947.69
template_file: templates/disease_pathophysiology_research.md
template_sha: "f452f0a9c7e3536175154b9683c45663f686f283"
template_variables:
  disease_name: TUBA1C-related Preimplantation Embryonic Arrest
  mondo_id: MONDO:0979232
  category: Mendelian
  causal_genes: TUBA1C
  omim_id: OMIM:621232
  synonyms: OZEMA24; TUBA1C-related recurrent preimplantation embryo arrest
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
citation_count: 1
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: TUBA1C-related_Preimplantation_Embryonic_Arrest-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: TUBA1C-related_Preimplantation_Embryonic_Arrest-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** TUBA1C-related Preimplantation Embryonic Arrest
- **MONDO ID:** MONDO:0979232 (if available)
- **Causal gene(s):** TUBA1C
- **OMIM:** OMIM:621232
- **Synonyms:** OZEMA24; TUBA1C-related recurrent preimplantation embryo arrest
- **Category:** Mendelian

Many disease names are serial numbers ("... autosomal dominant 64", "... 26") that
do not say which gene the disease is about, and a similarly named disease with a
different gene is easy to research by mistake. Research the disease with the MONDO
ID and causal gene given above, and name its causal gene in your first paragraph.
If the name seems to point to a different gene or OMIM entry, follow the
identifiers above.

## Research Objectives

Please provide a comprehensive research report on **TUBA1C-related Preimplantation Embryonic Arrest** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# TUBA1C-related Preimplantation Embryonic Arrest (OZEMA24)
### Comprehensive Disease Characterization Report

**Causal gene: _TUBA1C_ (tubulin alpha 1c; HGNC:20768).** This report concerns the Mendelian disorder in which **biallelic (homozygous) loss-of-function variants in the α-tubulin isotype gene _TUBA1C_** cause female infertility presenting as recurrent preimplantation embryo arrest. Identifiers: **MONDO:0979232**, **OMIM:621232 (OZEMA24 — "oocyte/zygote/embryo maturation arrest 24")**. The disease is distinct from, but mechanistically parallel to, the better-known β-tubulin (_TUBB8_) oocyte/embryo-arrest disorders. Note also that a second α-tubulin gene, _TUBA4A_, was reported in the same study for RPEA, but _TUBA4A_ is separately and predominantly associated with neurodegenerative/myopathic phenotypes (ALS/FTD, SPAX11, CMYO26) — do not conflate the two.

> **Evidence base.** The disease entity rests almost entirely on a single primary human-genetics paper: **Hu H, Wan X, Zhang H, et al. "Biallelic variants in α-tubulin isotypes cause female infertility characterised as recurrent preimplantation embryo arrest." _J Med Genet_ 2024 Oct 23;61(11):1045–1052 (PMID: 39209701).** All TUBA1C-specific claims derive from this report; broader claims are supported by the tubulin/RPEA literature and are flagged as analogy/inference where appropriate.

---

## 1. Disease Information

- **Overview.** A rare Mendelian cause of female infertility in which fertilized eggs or early cleavage-stage embryos repeatedly stop developing before blastocyst formation/implantation, yielding no transferable embryos during IVF/ICSI. It belongs to the family of **recurrent preimplantation embryo arrest (RPEA / PREA / PREMBA)** disorders caused by defects in genes governing the oocyte meiotic and early-embryonic mitotic spindle.
- **Key identifiers.**
  - OMIM: **621232** (phenotype, OZEMA24)
  - MONDO: **MONDO:0979232** — label "oocyte/zygote/embryo maturation arrest 24" (confirmed via EBI OLS4)
  - MedGen: **UID 1876453**; UMLS: **C6012735** (MONDO equivalentTo cross-references)
  - Gene: _TUBA1C_ — **HGNC:20768**, **NCBI Gene 84790**, **Ensembl ENSG00000167553**, UniProt **Q9BQE3**
  - Orphanet / ICD-10 / ICD-11 / MeSH: No dedicated disease-level code identified for this ultra-new entity; it falls under female infertility (ICD-10 N97.x; ICD-11 GA31) and "female infertility of other origin." MeSH: closest terms "Infertility, Female" and "Embryo Loss."
- **Synonyms / alternative names.** OZEMA24; TUBA1C-related recurrent preimplantation embryo arrest; α-tubulin (TUBA1C)-related oocyte/embryo maturation arrest.
- **Information source.** Derived from **individual patients** (whole-exome sequencing of an RPEA cohort with functional validation), not from aggregated disease-level registries. The knowledge base is a small number of index cases.

## 2. Etiology

- **Primary cause — genetic.** Homozygous loss-of-function variants in _TUBA1C_. Two variants are reported (Hu et al. 2024): **p.Gln358Ter** (nonsense/stop-gain) and **p.Asp444Metfs\*42** (frameshift). Both are predicted loss-of-function and both were homozygous. Verbatim: *"Four homozygous variants were identified in the PREA cohort: two of TUBA1C (p.Gln358Ter and p.Asp444Metfs\*42) ... These variants cause varying degrees of spindle assembly defects"* (PMID 39209701).
- **Genetic risk factors.** The causal variants themselves are the risk determinant. **Consanguinity / homozygosity** is implicit (homozygous variants in a recessive disorder). Carrier (heterozygous) parents are unaffected. No susceptibility loci or modifier genes have been defined for this entity.
- **Environmental / lifestyle / infectious factors.** **None known or implicated.** This is a monogenic cytoskeletal disorder; there is no evidence for toxic, infectious, or lifestyle contributions. (Not applicable.)
- **Protective factors.** None defined. By mechanism, presence of at least one functional _TUBA1C_ allele (heterozygous carrier state) is "protective" (asymptomatic), consistent with recessive inheritance.
- **Gene–environment interactions.** None described. (Not applicable with current evidence.)

## 3. Phenotypes

The phenotype is **reproductive**, detected only in the context of attempted conception/ART. There are no somatic/systemic manifestations reported.

| Phenotype | Type | Onset | Severity | Frequency | Suggested HPO |
|---|---|---|---|---|---|
| Female infertility | Clinical sign | Reproductive age | Severe | 100% of affected | **HP:0008222** (Female infertility) / HP:0000133 |
| Recurrent preimplantation embryo arrest (no blastocyst) | Lab/clinical (ART) | At IVF/ICSI | Severe | 100% | HP:0030033 (Abnormal fertility) — no precise HPO; closest HP:0100678? N/A |
| Repeated IVF/ICSI failure (no transferable embryos) | Clinical observation | At ART | Severe | 100% | — |
| Meiotic spindle / early-cleavage spindle assembly defect | Lab/cellular | Oocyte–zygote | Variable ("varying degrees") | — | — |

- **Characteristics.** Onset is effectively **congenital at the gametic level** but clinically manifests only in **adulthood at reproductive age** when ART is attempted. Course is **stable/non-progressive** (a fixed reproductive block, not a degenerative disease). Severity is **severe** for the reproductive endpoint (recurrent failure).
- **Quality-of-life impact.** Substantial psychological and emotional burden typical of infertility and recurrent ART failure (anxiety, depression, relationship/financial strain), but **no physical disability or systemic illness**. No disease-specific QoL instrument data exist for TUBA1C; general infertility QoL tools (FertiQoL, SF-36) would apply.

## 4. Genetic / Molecular Information

- **Causal gene.** _TUBA1C_ — tubulin alpha 1c (12q13.12). One of the human α-tubulin isotypes forming the obligate α/β-tubulin heterodimer, the building block of microtubules.
- **Pathogenic variants (reference transcript NM_032704.5; both ClinVar "Pathogenic" for OZEMA24):**
  - **p.Gln358Ter** (ClinVar "Q358*", Variation ID 3901262) — nonsense (stop-gain) → predicted loss of function; **ClinVar Pathogenic** (ACMG PVS1 + recessive segregation).
  - **c.1330del → p.Asp444Metfs\*42** (ClinVar "TUBA1C, 1-BP DEL, NT1330", Variation ID 3901263) — single-base-deletion frameshift → truncation/loss of function; **ClinVar Pathogenic**.
  - Both are annotated in ClinVar to the condition **"Oocyte/zygote/embryo maturation arrest 24" (OZEMA24)**. The remainder of the TUBA1C ClinVar entry set is dominated by variants of uncertain significance (VUS), underscoring the novelty of these two LOF alleles.
  - Both **germline**, **homozygous (biallelic)**, **maternal-effect/embryonic**. No somatic involvement.
- **Functional consequence.** **Loss of function** (truncation/NMD-susceptible transcripts, loss of a functional α-tubulin isotype) leading to impaired spindle assembly. (Contrast: _TUBB8_ disease variants are typically **dominant-negative missense** that poison heterodimer assembly.)
- **Allele frequency.** The specific LOF variants are ultra-rare/absent or near-absent in population databases (gnomAD) consistent with a severe recessive phenotype.
- **Gene constraint (gnomAD, this analysis).** _TUBA1C_ pLI = **0.055**, observed/expected LoF (oe_lof) = **0.458** (90% CI 0.31–0.70), missense Z = **4.55** (strongly missense-constrained), lof_z = 2.72. The tolerance of heterozygous LoF explains the **autosomal recessive** mode (carriers unaffected); strong missense constraint reflects structural sensitivity of the folded tubulin.
- **Modifier genes / epigenetics / chromosomal abnormalities.** None established for TUBA1C. (Of note, downstream single-cell RNA-seq of arrested embryos in the companion _TUBA4A_ cases showed altered spindle organisation, chromosome segregation and **mRNA decay** programs — relevant to mechanism, not a primary chromosomal lesion.)

## 5. Environmental Information

**Not applicable.** No environmental, lifestyle, toxic, or infectious factors contribute to this monogenic cytoskeletal disorder.

## 6. Mechanism / Pathophysiology

### Causal chain (initiating lesion → clinical manifestation)
1. **Biallelic LOF variant in _TUBA1C_** (p.Gln358Ter nonsense; p.Asp444Metfs\*42 frameshift) → **leads to** loss/truncation of functional TUBA1C α-tubulin protein (likely via nonsense-mediated decay and/or non-functional truncated polypeptide). *[demonstrated: variants identified; LOF inferred from variant class]*
2. Reduced functional α-tubulin pool → **results in** defective assembly of the **α/β-tubulin heterodimer** and impaired microtubule polymerization in the oocyte/early embryo. *[inferred from tubulin biology; TUBB8 paradigm]*
3. Impaired microtubule assembly → **leads to** **meiotic and early-mitotic spindle assembly defects** ("varying degrees of spindle assembly defects," PMID 39209701). *[demonstrated in vitro]*
4. Spindle defects → **cause** **chromosome mis-segregation / mitotic failure** and dysregulated maternal **mRNA decay / zygotic transition** programs in cleavage-stage embryos. *[demonstrated by single-cell RNA-seq in the companion α-tubulin (TUBA4A) cases; inferred for TUBA1C]*
5. Failed cell division → **results in** **arrest of preimplantation embryo development** before the blastocyst stage (no viable/transferable embryo). *[clinical observation]*
6. → **Clinical manifestation: recurrent IVF/ICSI failure and female infertility.**

**Branch point:** the lesion can manifest as (a) meiotic spindle failure at the oocyte stage and/or (b) first-cleavage mitotic spindle failure in the zygote/early embryo; the reported TUBA1C phenotype centers on **post-fertilization embryonic arrest** rather than pre-fertilization oocyte-maturation arrest, distinguishing it along the spectrum seen with TUBB8.

### Checklist coverage
- **Molecular pathways / processes.** Microtubule cytoskeleton assembly; mitotic/meiotic spindle organization; cell-cycle progression (M-phase); chromosome segregation; maternal mRNA clearance / maternal-to-zygotic transition. **GO terms:** GO:0007017 (microtubule-based process), GO:0000226 (microtubule cytoskeleton organization), GO:0007052 (mitotic spindle organization), GO:0007051 (spindle organization), GO:0051301 (cell division), GO:0007059 (chromosome segregation), GO:0045132 (meiotic chromosome segregation).
- **Protein dysfunction.** Loss of function of an α-tubulin isotype; impaired heterodimer formation and microtubule nucleation/dynamics. (CHEBI: GTP CHEBI:15996 — tubulin is a GTP-binding protein; paclitaxel-class CHEBI not therapeutically relevant here.) **Structural detail (UniProt Q9BQE3, 449 aa):** both variants converge on the **C-terminal acidic "E-hook" tail** (disordered region residues 429–449; sequence …KDYEEVGADSADGEDEGEEY). This tail carries regulatory PTM sites (phospho-Tyr432, phospho-Ser439) and the terminal **Tyr449** that undergoes the detyrosination/tyrosination cycle. **p.Gln358Ter** deletes ~92 C-terminal residues (~20% of the protein, removing the entire E-hook and part of the folded core); **p.Asp444Metfs\*42** spares the folded core but replaces the extreme C-terminal tail with 42 aberrant residues. The E-hook mediates binding of microtubule-associated proteins (MAPs), molecular motors, and +TIPs — so its loss impairs microtubule–MAP/motor interactions and spindle regulation in addition to any NMD-mediated null effect.
- **Cellular processes.** Cell-cycle/M-phase dysregulation, failed cytokinesis, developmental arrest (a form of division failure rather than classic apoptosis, though embryonic fragmentation/apoptosis can ensue).
- **Metabolic / immune / infectious involvement.** None. (Not applicable.)
- **Molecular profiling.** Single-cell/single-embryo RNA-seq of arrested embryos (companion α-tubulin cases) highlighted spindle organization, chromosome segregation and mRNA-decay transcriptomic disruption.
- **Expression note (mechanistic nuance).** Human Protein Atlas: _TUBA1C_ RNA is **"detected in all" tissues** and localizes to **microtubules** — i.e., TUBA1C is broadly/ubiquitously expressed, unlike oocyte-specific _TUBB8_. The oocyte/early-embryo-restricted phenotype despite ubiquitous expression implies the **uniquely error-intolerant meiotic/first-mitotic spindle** is the vulnerable window, where TUBA1C contributes substantially and other α-tubulin isotypes incompletely compensate.

**Cell types (CL):** oocyte **CL:0000023**, zygote/fertilized egg **CL:0000365**, embryonic cell/blastomere **CL:0000353**.

## 7. Anatomical Structures Affected

- **Organ level.** Primary: the **oocyte and preimplantation embryo** (female reproductive system). No secondary organ involvement. Body system: **reproductive system** only.
- **Tissue / cell level.** Germ cells — oocytes (**CL:0000023**), and the cleavage-stage embryo/blastomeres (**CL:0000353**); no somatic tissue pathology.
- **Subcellular level.** **Microtubule cytoskeleton / meiotic & mitotic spindle** (GO cellular component GO:0005874 microtubule; GO:0005819 spindle; GO:0072686 mitotic spindle). Localization confirmed to microtubules (HPA).
- **Localization (UBERON).** Ovary **UBERON:0000992**; oocyte-containing follicle; embryo **UBERON:0000922**. **Bilateral** (both ovaries / all oocytes affected); the defect is intrinsic to every gamete/embryo (not focal/lateralized).

## 8. Temporal Development

- **Onset.** The molecular lesion is **congenital/germline**; the clinical phenotype has an **adult (reproductive-age) presentation**, discovered only when pregnancy/ART is attempted. Onset pattern of the embryonic event is **acute per cycle** (arrest occurs within days of fertilization, typically cleavage stage, before blastocyst).
- **Progression.** **Non-progressive and stable** — a fixed reproductive block; not a staged or degenerative disease. The pattern is **recurrent/reproducible across IVF cycles** (hence "recurrent" embryo arrest).
- **Critical period / window of intervention.** The vulnerable window is **oocyte meiosis through the first few embryonic cleavage divisions**. There is no therapeutic window to rescue the patient's own oocytes; the only effective "intervention point" is to bypass the gametes (oocyte donation).

## 9. Inheritance and Population

- **Inheritance pattern.** **Autosomal recessive** (biallelic/homozygous LOF; unaffected heterozygous carriers). Consistent with gnomAD LoF tolerance (pLI 0.055).
- **Penetrance / expressivity.** Apparently **high penetrance** for the reproductive phenotype in homozygotes; **variable expressivity** at the cellular level ("varying degrees of spindle assembly defects"). No anticipation (not a repeat-expansion disorder).
- **Carrier frequency / founder effects / consanguinity.** Not formally estimated; homozygous presentation suggests **consanguinity or population homozygosity**. Cohort of Chinese ancestry (study from Central South University / Shandong University). No founder haplotype defined.
- **Epidemiology.** **Ultra-rare.** RPEA overall is uncommon; TUBA1C accounts for only a tiny minority of RPEA cases (two variants reported to date). No prevalence/incidence figures exist. **Sex:** manifests in **females** (maternal/embryonic effect); males homozygous for LOF have no reported reproductive phenotype attributable to TUBA1C in this study. **Geographic data:** index cases East Asian; too few to define distribution.

## 10. Diagnostics

- **Primary diagnostic route — genetic.** **Whole-exome sequencing (WES)** of the infertile woman (the discovery method), confirmed by **Sanger sequencing**; segregation in parents (carrier status). **WGS** or **targeted RPEA/oocyte-maturation-arrest gene panels** (which should now include _TUBA1C_ alongside _TUBB8, TUBA4A, PATL2, WEE2, TLE6, NLRP5, PADI6, KPNA7, GMNN, HFM1, MEI1, KIF11, CKAP5_) are the practical diagnostic tools. Single-gene testing is appropriate once a panel/WES flags _TUBA1C_.
- **Clinical/ART findings (phenotypic diagnosis).** Documentation at IVF/ICSI of **repeated embryonic arrest with no blastocyst/transferable embryo** despite normal oocyte retrieval; this ART phenotype prompts genetic testing. Time-lapse embryo morphokinetics can document the arrest.
- **Supportive research assays.** In vitro heterodimer-assembly/microtubule assays, immunofluorescence of spindle architecture, and **single-embryo/single-cell RNA-seq** (research, not clinical).
- **Not applicable:** CMA/karyotype/FISH (no structural chromosomal lesion), mtDNA testing, repeat-expansion testing, routine biochemistry/imaging — all normal/uninformative.
- **Differential diagnosis.** Other maternal-effect/spindle genes causing oocyte-maturation arrest, fertilization failure, or embryo arrest — especially **_TUBB8_** (dominant, oocyte-specific), **_TUBA4A_**, **_KIF11_, _CKAP5_** (spindle), and zygotic-genome-activation/cell-cycle genes (**_KPNA7_, _GMNN_, _HFM1_, _MEI1_, _PADI6_, _NLRP5_, _TLE6_, _WEE2_, _PATL2_**). Distinguished by gene identity, inheritance mode, and the precise developmental stage of arrest.
- **Screening.** No population newborn/carrier screening. **Cascade carrier testing** of relatives and **preconception carrier screening** in consanguineous couples are reasonable once a familial variant is known.

## 11. Outcome / Prognosis

- **Survival/mortality:** **Not applicable** — no effect on patient health or lifespan; the disease affects reproduction only.
- **Reproductive prognosis with own oocytes:** **Poor** — recurrent IVF/ICSI failure; by analogy to TUBB8/KIF11, **no viable pregnancies** have been documented with the patient's own gametes.
- **Prognosis with intervention:** **Good via oocyte donation** (bypasses the defective maternal gametes).
- **Morbidity:** Limited to infertility and its psychosocial impact; no physical disability.
- **Prognostic factors:** Variant severity (complete LOF) and the stage of arrest; essentially uniformly severe for the autologous-gamete endpoint.

## 12. Treatment

- **No pharmacological or gene/cell/RNA therapy exists**; no targeted drug. Microtubule-targeting drugs are not therapeutic here.
- **Standard of care:** **Genetic counseling + third-party reproduction (donor-oocyte IVF).** Supporting evidence (spindle-gene RPEA generally): Voros et al. 2025 (PMID 40650169): *"Donor egg IVF was the sole effective treatment; however, no viable pregnancies were documented in patients with pathogenic mutations of TUBB8 or KIF11."* Applied to TUBA1C by mechanistic analogy (no TUBA1C-specific outcome data yet).
- **Supportive care:** psychological support for infertility.
- **Experimental:** None specific. (NCIT suggestions: **In Vitro Fertilization** NCIT:C15387; **Oocyte Donation** — donor-gamete ART; **Genetic Counseling** NCIT:C15499.)
- **Pharmacogenomics / immunotherapy / surgery:** Not applicable.

## 13. Prevention

- **Primary prevention:** **Preconception / carrier genetic screening**, especially in consanguineous couples; **genetic counseling** with reproductive-risk assessment (25% recurrence for two carriers).
- **Reproductive options to avoid affected outcomes:** **Oocyte donation** (most effective); **PGT** is generally **not useful** for a maternal-effect/embryonic cytoskeletal defect because the patient's own embryos arrest before testing/transfer — so prevention centers on gamete donation rather than embryo selection.
- **Secondary/tertiary prevention, immunization, public-health/environmental measures:** Not applicable (monogenic, non-infectious, non-environmental).

## 14. Other Species / Natural Disease

- **Taxonomy / orthologs.** Human _TUBA1C_ (**NCBI Gene 84790**). Mouse ortholog **_Tuba1c_** (and the closely related _Tuba1a/Tuba1b_ cluster). α-tubulin is **deeply evolutionarily conserved** across eukaryotes; the α/β-tubulin spindle mechanism is universal. **HomoloGene/Alliance** confirm orthology.
- **Natural disease in other species:** **No naturally occurring TUBA1C-related embryo-arrest disease is catalogued** (e.g., not in OMIA) for companion animals/wildlife. (Not applicable with current data.)
- **Comparative biology:** The requirement of α-tubulin for meiotic/mitotic spindles is conserved, making the mechanism broadly generalizable, but the specific oocyte/embryo-restricted human phenotype reflects isotype usage and redundancy particular to primate/human early development.
- **Transmission / zoonosis:** Not applicable (genetic disease).

## 15. Model Organisms

- **No dedicated published _Tuba1c_-knockout model of embryo arrest** was identified. Functional validation to date is **in vitro / in cultured cells** and via **single-cell RNA-seq of human arrested embryos** (PMID 39209701).
- **Constitutive mouse _Tuba1c_ knockout does NOT recapitulate the human disease.** IMPC single-gene knockout data report only **"increased circulating alkaline phosphatase level"** (homozygote), with **viable homozygotes and no infertility/embryo-arrest phenotype**. This is a major model limitation, most plausibly reflecting **differential α-tubulin isotype redundancy** between mouse and human oocytes/early embryos (paralleling the primate-specificity of _TUBB8_). Oocyte-specific/humanized models or human iPSC-derived gamete/embryo systems would be required to recapitulate the phenotype.
- **Relevant comparative models (paradigm genes):** _TUBB8_ mutations have been studied in **cultured HeLa cells, yeast (microtubule dynamics), and mouse oocytes** (PMID 26789871, 27273344) — these recapitulate spindle-assembly disruption and establish the tubulin-spindle mechanism. Mouse _Tuba1c_ gene-targeting (IMPC/MGI) could serve as a future model; conditional/oocyte-specific knockouts would best recapitulate the human reproductive phenotype.
- **Model limitations:** _TUBB8_ is primate-specific (no true mouse ortholog), so mouse models imperfectly capture isotype-specific human oocyte biology; by extension, modeling the exact human TUBA1C contribution requires humanized or human-embryo systems (iPSC-derived gametes/organoids are emerging but not yet established for this gene).
- **Resources:** MGI (_Tuba1c_), IMPC/IMSR, Alliance of Genome Resources.

---

## Supported vs. Refuted Hypotheses

| Hypothesis | Status | Basis |
|---|---|---|
| Biallelic _TUBA1C_ LOF causes recurrent preimplantation embryo arrest | **Supported** | PMID 39209701: two homozygous LOF variants, spindle defects |
| Mechanism is α/β-tubulin spindle disruption (shared with TUBB8) | **Supported** | Functional assays; tubulin-spindle paradigm (26789871, 40650169) |
| Inheritance is autosomal recessive | **Supported** | Homozygous variants; gnomAD LoF tolerance (pLI 0.055) |
| Donor-oocyte IVF is the only effective management | **Supported (by analogy)** | PMID 40650169 for TUBB8/KIF11; inferred for TUBA1C |
| Environmental/lifestyle factors contribute | **Refuted / N.A.** | Monogenic cytoskeletal disorder; no evidence |
| Disease causes systemic/somatic illness | **Refuted** | Phenotype restricted to reproduction despite ubiquitous expression |

## Limitations and Future Directions

- The entire TUBA1C-specific evidence base is **one paper with two families/variants**; penetrance, expressivity, carrier frequency, and population distribution are essentially unknown.
- No animal model, no clinical trial, and no TUBA1C-specific treatment-outcome data exist.
- The precise explanation for an **oocyte/embryo-restricted phenotype from a ubiquitously expressed gene** (isotype redundancy, dosage, developmental spindle vulnerability) remains to be dissected.
- **Future work:** additional patient ascertainment to refine the variant/phenotype spectrum; oocyte-specific _Tuba1c_ mouse or human iPSC-gamete/organoid models; integration into clinical RPEA gene panels; and formal definition of the developmental stage(s) of arrest by time-lapse and single-cell multi-omics.

---

### Key Citations
- **PMID 39209701** — Hu et al., _J Med Genet_ 2024;61(11):1045–1052. Primary disease-defining paper (TUBA1C p.Gln358Ter, p.Asp444Metfs\*42; spindle defects; RPEA).
- **PMID 40650169** — Voros et al., _Int J Mol Sci_ 2025;26:6390. Systematic review (TUBB8/KIF11/CKAP5); donor-egg IVF as sole effective treatment.
- **PMID 26789871** — Feng et al., _N Engl J Med_ 2016. TUBB8 and human oocyte meiotic arrest (mechanistic paradigm).
- **PMID 27273344** — Feng et al., 2016. TUBB8 phenotypic spectrum (oocyte/early-embryo).
- **PMID 40455380 / 36647821 / 41423819** — GMNN / KPNA7 / HFM1 RPEA genes (differential diagnosis context).
- Gene/constraint data: Ensembl ENSG00000167553; gnomAD (pLI 0.055, oe_lof 0.458, mis_z 4.55); Human Protein Atlas (ubiquitous, microtubule localization).


## Artifacts

- [OpenScientist final report](TUBA1C-related_Preimplantation_Embryonic_Arrest-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](TUBA1C-related_Preimplantation_Embryonic_Arrest-deep-research-openscientist_artifacts/final_report.pdf)

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 25 |
| Resolved | 23 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 2 |
| Terms whose name was checked | 9 |
| Terms named correctly | 7 |
| Terms named as a **different** term | 2 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0979232` (3 mentions) - the report calls it "if available"; MONDO calls it **oocyte/zygote/embryo maturation arrest 24**
- `CHEBI:15996` (1 mention) - the report calls it "tubulin is a GTP-binding protein"; CHEBI calls it **GTP**

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `OMIM`.
